Madrigal Pharmaceuticals, Inc. (FRA:YDO1)
511.60
-1.60 (-0.31%)
At close: Nov 28, 2025
Madrigal Pharmaceuticals Revenue
Revenue (ttm)
$631.25M
Revenue Growth
+864.21%
P/S Ratio
17.93
Revenue / Employee
$1.20M
Employees
528
Market Cap
11.32B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 147.00K | -7.44M | -98.06% |
| Dec 31, 2011 | 7.58M | -7.22M | -48.77% |
| Dec 31, 2010 | 14.80M | -129.44M | -89.74% |
| Dec 31, 2009 | 144.25M | 141.63M | 5,416.06% |
| Dec 31, 2008 | 2.62M | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
| SAP SE | 36.49B |
Madrigal Pharmaceuticals News
- 10 days ago - Madrigal Pharmaceuticals (MDGL) Sees Analyst Upgrade with Target Price Raised to $620 | MDGL ... - GuruFocus
- 11 days ago - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 11 days ago - Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 11 days ago - Madrigal Pharmaceuticals (MDGL): Oppenheimer Raises Price Target to $650 | MDGL Stock News - GuruFocus
- 12 days ago - Madrigal Pharmaceuticals (MDGL) Rating Maintained and Price Target Raised by Truist Securities ... - GuruFocus
- 14 days ago - Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences - GlobeNewsWire
- 18 days ago - Madrigal Pharmaceuticals (MDGL): Analyst Maintains Buy Rating, Raises Price Target | MDGL Stock News - GuruFocus
- 19 days ago - MDGL Crosses Above Average Analyst Target - Nasdaq